TD Cowen analyst Daniel Brennan upgraded the rating on Tempus AI, Inc. Class A to a Buy today, setting a price target of $65.00.
Meet Samuel – Your Personal Investing Prophet
High conviction TEM bulls now have this Tradr ETFDaniel Brennan has given his Buy rating due to a combination of factors, notably the more attractive risk‑reward after a share price drop of over 50% while business trends have actually improved. He sees the core Insights data franchise, built on a large, differentiated multimodal dataset, becoming more valuable as pharmaceutical companies ramp up their use of AI tools in research, supporting faster growth and potential outperformance versus current 2026 expectations.
He also believes the market is overstating the threat that generative AI poses to Tempus’s data business, arguing that its specialized, longitudinal datasets should make it a key beneficiary rather than a loser. In addition, he highlights a solid trajectory for the Genomics segment, with what he views as conservative volume assumptions, emerging pricing tailwinds from future FDA approvals and reimbursement changes, and overall upside that supports a $65 target price implying meaningful appreciation from current levels.
In another report released on March 30, Guggenheim also maintained a Buy rating on the stock with a $60.00 price target.